More

    Europe Markets

    Voriconazole Hikma (previously Voriconazole Hospira)

    OverviewThis is a summary of the European public assessment report (EPAR) for Voriconazole Hikma. It explains how the Agency assessed the medicine to...

    Rivastigmine Hexal | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

    SomaKit TOC | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for SomaKit TOC. It explains how the Agency assessed the medicine to...

    Entresto | European Medicines Agency (EMA)

    OverviewEntresto is a heart medicine used in adults with chronic (long-term) heart failure who have symptoms of the disease and reduced ejection fraction...

    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

    Medicines containing semaglutide: PRAC investigating risk of rare eye conditionPRAC will assess risk of non-arteritic anterior ischemic optic neuropathy (NAION)EMA’s safety committee, PRAC,...

    Twynsta | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Twynsta. It explains how the Committee for Medicinal Products for Human...

    Pravafenix | European Medicines Agency (EMA)

    OverviewPravafenix is used in adults at high risk of heart disease whose low-density-lipoprotein (LDL) cholesterol is already being controlled with pravastatin alone or...

    Two new vaccines against bluetongue recommended for approval

    EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 to protect sheep against bluetongue disease. Bluevac-3 is also approved...

    PritorPlus | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for PritorPlus. It explains how the Committee for Medicinal Products for Human...

    MicardisPlus | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for MicardisPlus. It explains how the Committee for Medicinal Products for Human...

    Kinzalkomb | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Kinzalkomb. It explains how the Committee for Medicinal Products for Human...

    Opening procedures at EMA to non-EU authorities (OPEN) framework

    Participating organisations The OPEN framework relies on permanent confidentiality...

    Gavreto | European Medicines Agency (EMA)

    OverviewThe marketing authorisation for Gavreto has been withdrawn at the request of the marketing-authorisation holder. ...

    Mayzent | European Medicines Agency (EMA)

    OverviewMayzent is a medicine used to treat adults with an advanced form of multiple sclerosis (MS) known as secondary progressive MS.It is used...

    Vaxneuvance | European Medicines Agency (EMA)

    OverviewVaxneuvance is a vaccine used to protect against three types of infections caused by the bacterium Streptococcus pneumoniae (S. pneumoniae):acute otitis media (ear...

    Palforzia | European Medicines Agency (EMA)

    OverviewPalforzia is a medicine for treating peanut allergy in children from 1 to 17 years of age and patients who become adults whilst...